Not a real patient.
Recurrent Uterine Leiomyosarcoma Treated With Gemcitabine/Taxane Patient Profile
Vicky is a postmenopausal, 55-year-old Caucasian woman. She is married with 3 adult children. She works full-time as an office manager in a busy law practice. She is a nonsmoker who exercised regularly until she started experiencing pain, which slowed her down. She drinks socially, and the only medication she takes is daily aspirin.
Vicky presented to her gynecologist with abnormal vaginal bleeding and pelvic/ abdominal pain. The suspected diagnosis was uterine leiomyosarcoma. A biopsy confirmed the diagnosis. Her treatment included a total hysterectomy and salpingo-oophorectomy. The pathology report revealed a 6-cm uterine leiomyosarcoma, confined to the uterus. Vicky was referred to a multidisciplinary oncology center for follow-up.
Postsurgical surveillance at 18 months revealed multiple lung nodules. Vicky received a full course of combination chemotherapy (gemcitabine and a taxane). Disease progression was observed within 6 months of treatment initiation.
Third-line treatment considerations
After progression, Vicky was treated with 3 cycles of doxorubicin/ifosfamide. After 3 months, progression was again observed. Having normal hepatic function, YONDELIS® (trabectedin) 1.5 mg/m2 was administered over 24 hours as an IV infusion every 3 weeks until disease progression or unacceptable toxicity.